Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1, a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27.

You may also be interested in...



Mersana Moves Into Antibody-Drug Conjugates With Endo Collaboration

Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.

Seattle Genetics Looks Ahead To BLA Filing For Its Antibody Drug Conjugate

With positive top-line pivotal trial results for its lead antibody drug conjugate SGN-35 for Hodgkin's lymphoma in hand, Seattle Genetics aims to file a BLA for the compound in the first half of 2011 and is hoping as well for priority review

Seattle Genetics Looks Ahead To BLA Filing For Its Antibody Drug Conjugate

With positive top-line pivotal trial results for its lead antibody drug conjugate SGN-35 for Hodgkin's lymphoma in hand, Seattle Genetics aims to file a BLA for the compound in the first half of 2011 and is hoping as well for priority review

Related Content

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel